Limits...
The Czech Surveillance System for Invasive Pneumococcal Disease, 2008-2013: A Follow-Up Assessment and Sensitivity Estimation.

Stock NK, Maly M, Sebestova H, Orlikova H, Kozakova J, Krizova P - PLoS ONE (2015)

Bottom Line: Before PCV introduction in the Czech Republic in 2010, a national surveillance system for IPD was implemented in 2008 and further improved in 2011.An effect of the PVC vaccination in the Czech Republic is visible in the incidence of IPD in target age groups (<5 y).In 2013, an increase in the IPD incidence was observed.

View Article: PubMed Central - PubMed

Affiliation: National Institute of Public Health (NIPH), Prague, Czech Republic; European Program for Public Health Microbiology (EUPHEM), ECDC, Stockholm, Sweden.

ABSTRACT

Background: Invasive pneumococcal disease (IPD) is caused by Streptococcus pneumoniae and mostly presents as pneumonia, sepsis or meningitis. A notable portion of IPD cases is vaccine preventable and the pneumococcal conjugate vaccine (PCV) was introduced into the routine childhood immunization programs in many countries during the last decades.

Objectives: Before PCV introduction in the Czech Republic in 2010, a national surveillance system for IPD was implemented in 2008 and further improved in 2011. In this study, we describe the new surveillance system for the first time and measure its sensitivity between 2010 and 2013 using the capture-recapture method. Furthermore, we describe the recent epidemiological trend of IPD, taking sensitivity estimates into account.

Results and conclusions: Between 2010 and 2013 the estimated sensitivity of the overall IPD surveillance increased from 81% to 99%. The sensitivity of individual reporting sources increased from 72% to 87% for the laboratory system and from 31% to 89% for the epidemiological notification system. Crucial for this improvement was the introduction of quarterly report reminders in 2011. Due to positive source dependency, the presented sensitivity estimates are most probably overestimated and reflect the upper limit of reporting completeness. Stratification showed variation in sensitivity of reporting particularly according to region. An effect of the PVC vaccination in the Czech Republic is visible in the incidence of IPD in target age groups (<5 y). This influence was not evident in the total IPD incidence and may interfere with increasing sensitivity of reporting. In 2013, an increase in the IPD incidence was observed. This finding requires further observation and a detailed vaccine impact analysis is needed to assess the current immunization strategy.

No MeSH data available.


Related in: MedlinePlus

Timeline of events related to the introduction of PCV vaccination and IPD surveillance in the Czech Republic, 2005–2013.* Licensed and available on the private market.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4488342&req=5

pone.0131117.g001: Timeline of events related to the introduction of PCV vaccination and IPD surveillance in the Czech Republic, 2005–2013.* Licensed and available on the private market.

Mentions: In the Czech Republic (CZ), the first PCV (PCV7) was registered in 2005 and was available for immunization in the private market (Fig 1). With respect to the registration of PCV10 (2009) and PCV13 (2010), a comprehensive national surveillance system for IPD was piloted in 2007, replacing the non-compulsory laboratory system described previously [7,8]. Since 2008 IPD reporting is mandatory and in 2010 vaccination with PCV10 and PCV13 was included in the Czech national childhood immunization program, following an immunization schedule of 3+1 at 2, 3, 4 and 12 months of age (Fig 1).


The Czech Surveillance System for Invasive Pneumococcal Disease, 2008-2013: A Follow-Up Assessment and Sensitivity Estimation.

Stock NK, Maly M, Sebestova H, Orlikova H, Kozakova J, Krizova P - PLoS ONE (2015)

Timeline of events related to the introduction of PCV vaccination and IPD surveillance in the Czech Republic, 2005–2013.* Licensed and available on the private market.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4488342&req=5

pone.0131117.g001: Timeline of events related to the introduction of PCV vaccination and IPD surveillance in the Czech Republic, 2005–2013.* Licensed and available on the private market.
Mentions: In the Czech Republic (CZ), the first PCV (PCV7) was registered in 2005 and was available for immunization in the private market (Fig 1). With respect to the registration of PCV10 (2009) and PCV13 (2010), a comprehensive national surveillance system for IPD was piloted in 2007, replacing the non-compulsory laboratory system described previously [7,8]. Since 2008 IPD reporting is mandatory and in 2010 vaccination with PCV10 and PCV13 was included in the Czech national childhood immunization program, following an immunization schedule of 3+1 at 2, 3, 4 and 12 months of age (Fig 1).

Bottom Line: Before PCV introduction in the Czech Republic in 2010, a national surveillance system for IPD was implemented in 2008 and further improved in 2011.An effect of the PVC vaccination in the Czech Republic is visible in the incidence of IPD in target age groups (<5 y).In 2013, an increase in the IPD incidence was observed.

View Article: PubMed Central - PubMed

Affiliation: National Institute of Public Health (NIPH), Prague, Czech Republic; European Program for Public Health Microbiology (EUPHEM), ECDC, Stockholm, Sweden.

ABSTRACT

Background: Invasive pneumococcal disease (IPD) is caused by Streptococcus pneumoniae and mostly presents as pneumonia, sepsis or meningitis. A notable portion of IPD cases is vaccine preventable and the pneumococcal conjugate vaccine (PCV) was introduced into the routine childhood immunization programs in many countries during the last decades.

Objectives: Before PCV introduction in the Czech Republic in 2010, a national surveillance system for IPD was implemented in 2008 and further improved in 2011. In this study, we describe the new surveillance system for the first time and measure its sensitivity between 2010 and 2013 using the capture-recapture method. Furthermore, we describe the recent epidemiological trend of IPD, taking sensitivity estimates into account.

Results and conclusions: Between 2010 and 2013 the estimated sensitivity of the overall IPD surveillance increased from 81% to 99%. The sensitivity of individual reporting sources increased from 72% to 87% for the laboratory system and from 31% to 89% for the epidemiological notification system. Crucial for this improvement was the introduction of quarterly report reminders in 2011. Due to positive source dependency, the presented sensitivity estimates are most probably overestimated and reflect the upper limit of reporting completeness. Stratification showed variation in sensitivity of reporting particularly according to region. An effect of the PVC vaccination in the Czech Republic is visible in the incidence of IPD in target age groups (<5 y). This influence was not evident in the total IPD incidence and may interfere with increasing sensitivity of reporting. In 2013, an increase in the IPD incidence was observed. This finding requires further observation and a detailed vaccine impact analysis is needed to assess the current immunization strategy.

No MeSH data available.


Related in: MedlinePlus